Microdosing and human drug absorption studies under the spotlight in live web cast
Strategies to improve decision-making in early drug development will be under the spotlight on November 4th 2004 when one of the industry's leading early phase specialists hosts a web-based discussion and presentation.
The on-line sessions have been designed by Pharmaceutical Profiles (Nottingham, UK) to provide an informative and thought-provoking overview to help highlight the key challenges facing the pharmaceutical industry and examine innovative solutions to typical problems.
It is the company's second major webinar. The first was 'attended' on-line by more than 60 key industry delegates and was delivered by Professor Ian Wilding, a frequent speaker at international meetings and a respected authority on drug delivery and intestinal absorption. He will also deliver the second webinar.
The presentation will include an overview of the current drug development process and whether it is in need of real innovation, Phase 0 PK/ADME studies and the benefits of utilising microdosing technologies, employing microdosing investigations to increase productivity in early drug development, human drug absorption studies as a 'route map' for product development and choosing the correct enabling technologies using human drug absorption investigations.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.